National Comprehensive Cancer Network
3025 Chemical Road, Suite 100
About National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of 28 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system.
By defining and advancing high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers around the world. World-renowned experts from NCCN Member Institutions diagnose and treat patients with a broad spectrum of cancers and are recognized for dealing with complex, aggressive, or rare cancers. NCCN Member Institutions pioneered the concept of the multidisciplinary team approach to patient care and conduct innovative research that contributes significantly to understanding, diagnosing, and treating cancer. NCCN programs offer access to expert physicians, superior treatment, and quality and safety initiatives that continuously improve the effectiveness and efficiency of cancer care globally.
NCCN 20th Anniversary Video - Improving Cancer Care Together
January 31, 2015 marked the 20th anniversary of the National Comprehensive Cancer Network; originally announced as an alliance of 13 leading cancer centers in 1995, NCCN has grown to a network of 26 academic cancer centers devoted to patient care, research, and education.
Featuring past and present leadership, this video describes the groundbreaking accomplishments of NCCN over the past two decades that have improved the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.
140 articles about National Comprehensive Cancer Network
New Resource from National Comprehensive Cancer Network Breaks the Silence on Common but Lesser-Known Cause of Cancer Deaths
The National Comprehensive Cancer Network announced the publication of a new supportive care patient guideline focused on preventing and treating cancer-associated blood clots, also known as venous thromboembolism.
Most Non-English Speakers in the U.S. Are Turned Away Before Their First Cancer Visit According to New Research in JNCCN
New research in the September 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network reveals an alarming lack of access for non-English speakers who called hospitals across the United States looking for information on cancer care services.
The National Comprehensive Cancer Network® Oncology Research Program announced grants awarded to foster and enhance quality-of-care, guideline concordance, and innovations in care delivery for patients with limited-stage and extensive-stage small cell lung cancer.
Crystal S. Denlinger, MD, FACP, Named New CEO of National Comprehensive Cancer Network; Robert W. Carlson, MD, Retiring After 10+ Years Leading Global Oncology Nonprofit
The National Comprehensive Cancer Network® —a not-for-profit alliance of leading academic cancer centers—announced Crystal S. Denlinger, MD, FACP, as incoming Chief Executive Officer.
New and Updated Resources Published to Help Guide Oncology Care in the Middle East and North Africa (MENA)
The National Comprehensive Cancer Network® announced that a library of resources for improving cancer care in the Middle East and North Africa has been updated and expanded in collaboration with regional experts.
NCCN Convenes Policy Summit Assessing Impact of Geography on Cancer Outcomes, Examining Rural and Urban Divide
The National Comprehensive Cancer Network® —an alliance of leading cancer centers—convened a policy summit to examine how geography impacts cancer outcomes.
National Comprehensive Cancer Network Joins Collaboration to Improve Standards in Cancer Care for Vietnam
The National Comprehensive Cancer Network® announced the signing of a Memo of Understanding with Vietnam National Cancer Hospital and the Vietnam Cancer Association to work together to improve standards for cancer care throughout the country.
The National Comprehensive Cancer Network® and the NCCN Foundation® announced four winners for the 2023 NCCN Foundation Young Investigator Awards.
Deciphera Pharmaceuticals Announces QINLOCK® Included in NCCN Guidelines® for the Treatment of Second-Line GIST Patients & FDA Grants Breakthrough Therapy Designation for QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 & 17/18
Deciphera Pharmaceuticals, Inc. announced that QINLOCK® has been included in the latest National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology as a preferred regimen for second-line gastrointestinal stromal tumor patients intolerant to sunitinib.
New Research in JNCCN Highlights the Negative Impact of Continued Exclusion of Racial Groups from Research on Cancer Genomics
New research in the March 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network highlights how the lack of genomic research for people with African ancestry, particularly those from the Sub-Saharan region, is hampering efforts to reduce disparities for people with cancer.
New research in the January 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that immunotherapy from immune checkpoint inhibitors prior to surgery was strikingly effective for patients with localized mismatch repair-deficient or microsatellite instability-high colorectal cancer.
Cancer Screening Gaps Highlight Urgent Need to Address Health Inequities, According to NCCN Policy Summit
The National Comprehensive Cancer Network® hosted a policy summit to examine practice changes and trends in legislative and regulatory efforts that affect patient access to cancer screening and risk reduction.
Chemotherapy Drugs from "Rogue" Online Pharmacies Could Endanger Leukemia Patients, Suggests Research in JNCCN
Patients seeking to purchase chemotherapy drugs online face a confusing array of websites, over half of which potentially operate unsafely or illegally, finds a new study in the July 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network.
The National Comprehensive Cancer Network® announced the recipients of 2022 awards for both internal and external champions advancing NCCN's mission and helping all people with cancer to live better lives.
New research in the April 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network found the rate of mammography use by breast cancer survivors has been steadily declining since 2009, particularly among younger survivors.
NCCN Announces Indiana University Melvin and Bren Simon Comprehensive Cancer Center as 32nd Member Institution
Tthe National Comprehensive Cancer Network® announced Indiana University Melvin and Bren Simon Comprehensive Cancer Center will be joining the not-for-profit alliance of leading cancer centers as the 32nd Member Institution.
NCCN Pharmacy Directors Forum Publishes Recommendations for Safely Dispensing Investigational Medications for Clinical Trials
The National Comprehensive Cancer Network® announced the publication of new expert consensus recommendations to address routine problems that can occur during prescribing, receiving, storing, preparing, and delivering investigational drugs.
Seattle Cancer Care Alliance Clinicians Present New Research at 63rd Annual Meeting of the American Society of Hematology
Seattle Cancer Care Alliance, the only National Comprehensive Cancer Network -designated cancer center in Washington state, announced that more than 20 of the organization’s clinicians will showcase new research at the 63rd Annual Meeting of the American Society of Hematology, taking place December 11-14, 2021, in Atlanta.
NCCN Announces Funding for Early-Stage Non-Small Cell Lung Cancer Projects, in Collaboration with AstraZeneca
The National Comprehensive Cancer Network's Oncology Research Program to oversee projects focused on improving patient care and outcomes in early-stage non-small cell lung cancer.
NCCN Announces Funding for Prostate Cancer Research Projects, in Collaboration with Pfizer and Astellas
The National Comprehensive Cancer Network's Oncology Research Program to oversee projects focused on the use of enzalutamide in treating people with prostate cancer.